Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news

This share is rocketing on Friday after accepting a takeover offer.

| More on:
two men shake hands on a deal.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mayne Pharma Group Ltd (ASX: MYX) shares are catching the eye on Friday with a very strong gain.

In morning trade, the ASX 300 healthcare stock is up 34% to $7.25.

Why is this ASX 300 healthcare stock rocketing?

Investors have been scrambling to buy the company's shares this morning after it revealed that it has accepted a takeover offer.

According to the release, the company has entered into a scheme implementation deed with Cosette Pharmaceuticals that will see the latter acquire 100% of the shares in Mayne Pharma by way of a scheme of arrangement.

The two parties have agreed a price of $7.40 per share, which represents a 36.8% premium to where the ASX 300 healthcare stock last traded.

Cosette Pharmaceuticals is a US based pharmaceutical company with a portfolio of products in women's health and dermatology.

The company highlights that it has a history in the manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions, and suppositories. It has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by 350 plus team members across all functional areas.

The release notes that Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane (NASDAQ: HLNE)., a private markets investment management firm.

Unanimously recommended

The Mayne Pharma board advised that it unanimously recommends that shareholders vote in favour of the scheme. This is in the absence of a superior proposal and subject to the independent expert's report.

The company's two largest shareholders, Viburnum Funds and Bruce Mathieson, who collectively own a 14.1% stake, intend to vote in favour of the scheme.

'A pivotal moment'

The ASX 300 healthcare stock's chair, Frank Condella, was pleased with the deal. He said:

We are pleased that Cosette has recognised significant value in Mayne Pharma, particularly in our women's health and dermatology businesses, and the offer provides shareholders with the opportunity to receive cash value at a significant premium. The Board believes that the proposed transaction is in line with the Board's priority to deliver value to our shareholders, and also provides significant benefits for our broader stakeholders.

This sentiment was echoed by the company's CEO, Shawn Patrick O'Brien. He said:

Today marks a pivotal moment in Mayne's journey to improve patient access to life-enhancing medications. Attracting an offer from a strategic buyer who is active in the US Dermatology and Women's Health markets, such as Cosette, reflects the excellent work our teams have been doing to strengthen our company over the last year and more.

Having broadened our portfolio in Dermatology and Women's Health, and improved patient access through a refined US channel strategy, we have executed against our corporate strategies with precision. As we enter this new chapter, we do so as a stronger, more agile company.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Healthcare Shares

These healthcare stocks could be set to double according to broker

Interested in gaining exposure to the healthcare sector? These options could be ones to watch. 

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Up 250% in a year, how much higher can this ASX healthcare share climb?  

The future looks promising for this biotech firm after delivering a record-quarterly result.

Read more »

shadow of a man looking out a window with arrows signifying falling share price
Healthcare Shares

Macquarie expects this ASX All Ords healthcare stock to fall 21% in FY26

The company faces several headwinds across multiple divisions.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Top broker names the best ASX healthcare shares to buy in FY26

Bell Potter has good things to say about these shares.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is jumping on record quarter?

This stock reported record sales during the past three months.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'

If you haven’t heard of this fast-rising ASX 200 stock yet, that’s about to change.

Read more »